Earendil Labs Raises USD 787m to Advance AI-Driven Biologics Pipeline
Earendil Labs, a Wilmington, Delaware-headquartered biotechnology company focused on AI-driven biologics discovery and development, has closed USD 787 million in financing. The Earendil Labs funding will support the expansion of the company's computational platform and advance a pipeline of antibody and biologics programs targeting autoimmune diseases, cancer, and other indications, the company said.
The round drew participation from Dimension Capital, DST Global, INCE Capital, Luminous Ventures, Miracle Capital, Sanofi, and the Biotech Development Fund, a vehicle created by Hillhouse and Pfizer. Additional existing and new technology- and healthcare-focused investors also participated. The company did not disclose the specific series designation of the round. Earendil Labs said it plans to use the capital to scale its research and development operations, expand interdisciplinary teams across science, engineering, and translational medicine, advance multiple internal programs toward clinical milestones, and deepen strategic partnerships.
Earendil Labs describes its platform as an AI-native engine that integrates artificial intelligence across the full lifecycle of biologics research and development, from target identification through candidate design, optimization, and clinical progression. The platform is built around computational approaches to protein engineering, enabling the generation and multi-parameter optimization of antibody-based therapeutics. The company said the platform has produced more than 40 programs to date, spanning multiple disease areas and modalities including half-life extended antibodies and bispecific antibodies.
The company's lead candidate is HXN-1001, a half-life extended anti-TL1A antibody that Earendil Labs said is ready for Phase 2 clinical development. TL1A is a cytokine implicated in inflammatory and autoimmune pathology, and several companies are pursuing anti-TL1A approaches across indications including inflammatory bowel disease. Additional IND submissions are planned for 2026 and 2027, though the company has not disclosed specific candidates or indications beyond its lead program and two partnered assets.